- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Authors
Keywords
-
Journal
European Journal of Preventive Cardiology
Volume -, Issue -, Pages 204748731984531
Publisher
SAGE Publications
Online
2019-05-08
DOI
10.1177/2047487319845314
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
- (2019) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mendelian Randomization Study of ACLY and Cardiovascular Disease
- (2019) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
- (2019) Jane Armitage et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials
- (2019) M. Ruscica et al. EXPERT OPINION ON PHARMACOTHERAPY
- Lipid-Lowering Agents
- (2019) Robert A. Hegele et al. CIRCULATION RESEARCH
- Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction
- (2018) Jah Yeon Choi et al. AMERICAN JOURNAL OF CARDIOLOGY
- Hepatic Overexpression of Endothelial Lipase Lowers High-Density Lipoprotein but Maintains Reverse Cholesterol Transport in MiceHighlights
- (2018) Shunichi Takiguchi et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
- (2018) Christie M. Ballantyne et al. ATHEROSCLEROSIS
- Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα
- (2018) Yuta Yamamoto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD)
- (2018) Isao Taguchi et al. CIRCULATION
- Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia ― An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS) ―
- (2018) Satoshi Kodera et al. CIRCULATION JOURNAL
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes
- (2018) Charlotte Koopal et al. DIABETES CARE
- Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
- (2018) François Mach et al. EUROPEAN HEART JOURNAL
- Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial
- (2018) Katsumi Miyauchi et al. International Heart Journal
- PPAR Agonists and Metabolic Syndrome: An Established Role?
- (2018) Margherita Botta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe
- (2018) Mariko Harada-Shiba et al. Journal of Atherosclerosis and Thrombosis
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Comparative Evaluation of Gemcabene and Peroxisome Proliferator–Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator–Activated Receptors
- (2018) Charles L. Bisgaier et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
- (2018) Shizuya Yamashita et al. Journal of Clinical Lipidology
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Cholesteryl ester transfer protein and its inhibitors
- (2018) Sudichhya Shrestha et al. JOURNAL OF LIPID RESEARCH
- Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
- (2018) Om P. Ganda et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial
- (2018) Bum Joon Kim et al. LANCET NEUROLOGY
- Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism
- (2018) Rai Ajit K. Srivastava et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Present therapeutic role of cholesteryl ester transfer protein inhibitors
- (2018) Nicola Ferri et al. PHARMACOLOGICAL RESEARCH
- Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH
- (2018) Daniela Carmen Oniciu et al. PLoS One
- Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice
- (2018) José Tuñón et al. European Journal of Preventive Cardiology
- ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease
- (2018) Steven E. Nissen et al. JAMA Cardiology
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks
- (2018) Theingi Aung et al. JAMA Cardiology
- Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
- (2018) Stephen J. Nicholls et al. CLINICAL CARDIOLOGY
- Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists
- (2018) Shizuya Yamashita et al. ATHEROSCLEROSIS
- Hypertriglyceridaemia — REDUCE-IT with icosapent ethyl
- (2018) Gregory B. Lim Nature Reviews Cardiology
- Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
- (2018) JoAnn E. Manson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 — A Journey to Cardiovascular Outcomes
- (2018) John R. Burnett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies
- (2017) Christian M. Madsen et al. EUROPEAN HEART JOURNAL
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
- (2017) Brian A Ference et al. EUROPEAN HEART JOURNAL
- PPAR-α agonists are still on the rise: an update on clinical and experimental findings
- (2017) Nicola Ferri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction
- (2017) Maria-Corina Serban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Hypertriglyceridaemia and risk of coronary artery disease
- (2017) Željko Reiner Nature Reviews Cardiology
- Angiopoietin-like 3 in lipoprotein metabolism
- (2017) Sander Kersten Nature Reviews Endocrinology
- Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
- (2017) Anna M. Diehl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
- (2017) Stephen L. Pinkosky et al. TRENDS IN MOLECULAR MEDICINE
- Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial
- (2017) Jun-Bean Park et al. Trials
- The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis
- (2017) Liping Du et al. European Journal of Preventive Cardiology
- Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial
- (2017) Judith A Aberg et al. Lancet HIV
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
- (2017) Marshall B. Elam et al. JAMA Cardiology
- Trials and Tribulations of CETP Inhibitors
- (2017) Alan R. Tall et al. CIRCULATION RESEARCH
- Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease
- (2016) Anette Varbo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease
- (2016) Shizuya Yamashita et al. Journal of Atherosclerosis and Thrombosis
- Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
- (2016) Julian C. van Capelleveen et al. Journal of Clinical Lipidology
- Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients
- (2016) Evan Stein et al. Journal of Clinical Lipidology
- Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies
- (2016) Harold E. Bays et al. PROSTAGLANDINS & OTHER LIPID MEDIATORS
- Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
- (2016) Stephen L. Pinkosky et al. Nature Communications
- A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States
- (2016) Sephy Philip et al. JOURNAL OF MEDICAL ECONOMICS
- Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver
- (2015) Sana Raza-Iqbal et al. Journal of Atherosclerosis and Thrombosis
- Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)
- (2015) Christie M. Ballantyne et al. Journal of Clinical Lipidology
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) G Kees Hovingh et al. LANCET
- Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome
- (2015) Harold E. Bays et al. Metabolic Syndrome and Related Disorders
- Elsibucol inhibits atherosclerosis following arterial injury: Multifunctional effects on cholesterol levels, oxidative stress and inflammation
- (2014) Sylvie Dussault et al. ATHEROSCLEROSIS
- Statin therapy and related risk of new-onset type 2 diabetes mellitus
- (2014) Massimiliano Ruscica et al. European Journal of Internal Medicine
- Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
- (2014) S. Matthijs Boekholdt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Triglycerides and cardiovascular disease
- (2014) Børge G Nordestgaard et al. LANCET
- HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
- (2014) Anand Rohatgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
- (2013) Harold E. Bays et al. American Journal of Cardiovascular Drugs
- Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin
- (2013) Miao Hu et al. Expert Opinion on Drug Metabolism & Toxicology
- Molecular Mediators for Raft-dependent Endocytosis of Syndecan-1, a Highly Conserved, Multifunctional Receptor
- (2013) Keyang Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
- (2013) John J.P. Kastelein et al. Journal of Clinical Lipidology
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Demystifying the management of hypertriglyceridaemia
- (2013) Gerald F. Watts et al. Nature Reviews Cardiology
- Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)
- (2013) Rene A. Braeckman et al. PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
- The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
- (2013) Robert A Hegele et al. Lancet Diabetes & Endocrinology
- Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)
- (2012) Harold E. Bays et al. Journal of Clinical Lipidology
- A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study
- (2012) Michael H. Davidson et al. Journal of Clinical Lipidology
- (n-3) Fatty Acids and Cardiovascular Health: Are Effects of EPA and DHA Shared or Complementary?
- (2012) Dariush Mozaffarian et al. JOURNAL OF NUTRITION
- Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)
- (2011) Harold E. Bays et al. AMERICAN JOURNAL OF CARDIOLOGY
- Probucol therapy improves long-term (>10-year) survival after complete revascularization: A propensity analysis
- (2011) Takatoshi Kasai et al. ATHEROSCLEROSIS
- Pitavastatin: Novel effects on lipid parameters
- (2011) M. John Chapman ATHEROSCLEROSIS SUPPLEMENTS
- Drug–drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel?
- (2011) Alberto Corsini et al. CURRENT MEDICAL RESEARCH AND OPINION
- Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan
- (2011) Shizuya Yamashita et al. Journal of Atherosclerosis and Thrombosis
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
- (2011) Amit V. Khera et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)
- (2009) Stephen J. Nicholls et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2008) R. Scott et al. DIABETES CARE
- Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial
- (2008) Jean-Claude Tardif et al. LANCET
- Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial
- (2007) Jean-Claude Tardif et al. ATHEROSCLEROSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started